Imperva Inc (NYSE:IMPV) was downgraded by equities research analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Saturday.

A number of other research analysts also recently weighed in on IMPV. UBS AG began coverage on shares of Imperva in a research report on Tuesday, June 6th. They set a “positive” rating and a $60.00 price objective on the stock. Zacks Investment Research upgraded shares of Imperva from a “hold” rating to a “strong-buy” rating and set a $52.00 price objective on the stock in a research report on Wednesday, August 2nd. Monness Crespi & Hardt increased their price objective on shares of Imperva from $55.00 to $57.00 and gave the company a “buy” rating in a research report on Friday, July 28th. Stifel Nicolaus restated a “hold” rating and set a $47.00 price objective on shares of Imperva in a research report on Friday, July 14th. Finally, Evercore ISI set a $56.00 price objective on shares of Imperva and gave the company a “buy” rating in a research report on Friday, July 28th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $51.25.

Shares of Imperva (IMPV) opened at 43.90 on Friday. Imperva has a 12-month low of $34.40 and a 12-month high of $57.24. The company’s market cap is $1.48 billion. The company has a 50 day moving average of $48.73 and a 200-day moving average of $45.22.

Imperva (NYSE:IMPV) last issued its quarterly earnings data on Thursday, July 27th. The software maker reported ($0.10) earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.05 by $0.15. The company had revenue of $74.44 million for the quarter, compared to the consensus estimate of $74.30 million. Imperva had a negative net margin of 4.69% and a negative return on equity of 5.00%. The firm’s revenue for the quarter was up 28.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.23) EPS. Equities research analysts anticipate that Imperva will post $0.81 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: This story was first published by Daily Political and is the sole property of of Daily Political. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.dailypolitical.com/2017/08/07/imperva-inc-impv-rating-lowered-to-sell-at-bidaskclub.html.

In other news, insider Amichai Shulman sold 3,089 shares of the firm’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $48.70, for a total transaction of $150,434.30. Following the sale, the insider now directly owns 100,151 shares in the company, valued at approximately $4,877,353.70. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CRO Michael D. Mooney sold 52,356 shares of the firm’s stock in a transaction on Wednesday, May 10th. The shares were sold at an average price of $47.51, for a total transaction of $2,487,433.56. Following the sale, the executive now owns 52,356 shares in the company, valued at $2,487,433.56. The disclosure for this sale can be found here. Insiders have sold a total of 60,302 shares of company stock worth $2,875,861 over the last 90 days. Insiders own 2.20% of the company’s stock.

Hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. boosted its position in Imperva by 4.6% in the first quarter. Vanguard Group Inc. now owns 2,339,441 shares of the software maker’s stock valued at $96,033,000 after buying an additional 102,779 shares during the last quarter. JPMorgan Chase & Co. boosted its position in Imperva by 2.2% in the first quarter. JPMorgan Chase & Co. now owns 1,627,998 shares of the software maker’s stock valued at $66,828,000 after buying an additional 34,653 shares during the last quarter. Clearbridge Investments LLC boosted its position in Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock valued at $51,826,000 after buying an additional 403,809 shares during the last quarter. Eagle Asset Management Inc. boosted its position in Imperva by 4.1% in the first quarter. Eagle Asset Management Inc. now owns 1,087,223 shares of the software maker’s stock valued at $44,630,000 after buying an additional 43,278 shares during the last quarter. Finally, North Run Capital LP boosted its position in Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock valued at $30,788,000 after buying an additional 681,772 shares during the last quarter. Hedge funds and other institutional investors own 92.72% of the company’s stock.

About Imperva

Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.

Analyst Recommendations for Imperva (NYSE:IMPV)

Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.